CO5261537A1 - Eteres de dicarboxilato de calcio, metoos para su preparacion y tratamiento de las enfermedades vasculares y diabetes con los mismos - Google Patents

Eteres de dicarboxilato de calcio, metoos para su preparacion y tratamiento de las enfermedades vasculares y diabetes con los mismos

Info

Publication number
CO5261537A1
CO5261537A1 CO01005267A CO01005267A CO5261537A1 CO 5261537 A1 CO5261537 A1 CO 5261537A1 CO 01005267 A CO01005267 A CO 01005267A CO 01005267 A CO01005267 A CO 01005267A CO 5261537 A1 CO5261537 A1 CO 5261537A1
Authority
CO
Colombia
Prior art keywords
eteres
diabetes
preparation
treatment
methods
Prior art date
Application number
CO01005267A
Other languages
English (en)
Spanish (es)
Inventor
Ando Howard Yoshihisa
Donald Eugene Butler
Dozeman Gary Jay
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CO5261537A1 publication Critical patent/CO5261537A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CO01005267A 2000-01-25 2001-01-24 Eteres de dicarboxilato de calcio, metoos para su preparacion y tratamiento de las enfermedades vasculares y diabetes con los mismos CO5261537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17782300P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
CO5261537A1 true CO5261537A1 (es) 2003-03-31

Family

ID=22650106

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01005267A CO5261537A1 (es) 2000-01-25 2001-01-24 Eteres de dicarboxilato de calcio, metoos para su preparacion y tratamiento de las enfermedades vasculares y diabetes con los mismos

Country Status (39)

Country Link
EP (1) EP1259474B1 (cg-RX-API-DMAC10.html)
JP (1) JP4750995B2 (cg-RX-API-DMAC10.html)
KR (1) KR20020073182A (cg-RX-API-DMAC10.html)
CN (1) CN1395555A (cg-RX-API-DMAC10.html)
AP (1) AP2002002587A0 (cg-RX-API-DMAC10.html)
AR (1) AR029436A1 (cg-RX-API-DMAC10.html)
AT (1) ATE431326T1 (cg-RX-API-DMAC10.html)
AU (1) AU2214001A (cg-RX-API-DMAC10.html)
BG (1) BG106851A (cg-RX-API-DMAC10.html)
BR (1) BR0107763A (cg-RX-API-DMAC10.html)
CA (1) CA2397960C (cg-RX-API-DMAC10.html)
CO (1) CO5261537A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20022474A3 (cg-RX-API-DMAC10.html)
DE (1) DE60138686D1 (cg-RX-API-DMAC10.html)
DK (1) DK1259474T3 (cg-RX-API-DMAC10.html)
DZ (1) DZ3239A1 (cg-RX-API-DMAC10.html)
EA (1) EA004862B1 (cg-RX-API-DMAC10.html)
EE (1) EE200200404A (cg-RX-API-DMAC10.html)
ES (1) ES2324281T3 (cg-RX-API-DMAC10.html)
GE (1) GEP20053428B (cg-RX-API-DMAC10.html)
GT (1) GT200100015A (cg-RX-API-DMAC10.html)
HN (1) HN2001000011A (cg-RX-API-DMAC10.html)
HU (1) HUP0204422A3 (cg-RX-API-DMAC10.html)
IL (1) IL150541A0 (cg-RX-API-DMAC10.html)
IS (1) IS6442A (cg-RX-API-DMAC10.html)
MA (1) MA26867A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA02007223A (cg-RX-API-DMAC10.html)
NO (1) NO20023526L (cg-RX-API-DMAC10.html)
NZ (1) NZ519550A (cg-RX-API-DMAC10.html)
OA (1) OA12166A (cg-RX-API-DMAC10.html)
PA (1) PA8510601A1 (cg-RX-API-DMAC10.html)
PE (1) PE20011064A1 (cg-RX-API-DMAC10.html)
PL (1) PL357076A1 (cg-RX-API-DMAC10.html)
SK (1) SK10622002A3 (cg-RX-API-DMAC10.html)
SV (1) SV2002000290A (cg-RX-API-DMAC10.html)
TN (1) TNSN01013A1 (cg-RX-API-DMAC10.html)
UY (1) UY26550A1 (cg-RX-API-DMAC10.html)
WO (1) WO2001055078A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200205880B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1045691T1 (en) * 1997-12-12 2005-04-30 Warner-Lambert Company Llc Statin-carboxyalkylether combinations
JP2006501238A (ja) * 2002-08-22 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 骨関節炎を治療する方法
US7816405B2 (en) 2005-04-19 2010-10-19 Eisai R&D Management Co., Ltd. Calcium bis [(2S)-3-[3-[(2S)-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof
JPWO2006115130A1 (ja) * 2005-04-19 2008-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 ビス[(2s)−3−[3−[(2s)−3−(4−クロロ−2−シアノフェノキシ)−2−フルオロプロポキシ]フェニル]−2−イソプロポキシプロピオン酸]カルシウム及びその中間体
EP3218349A2 (en) * 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME
JP2022505033A (ja) * 2018-10-18 2022-01-14 ジェムフィアー セラピューティクス インコーポレイテッド ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
NZ503982A (en) 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus

Also Published As

Publication number Publication date
BR0107763A (pt) 2002-11-12
MXPA02007223A (es) 2002-11-29
IS6442A (is) 2002-06-25
DK1259474T3 (da) 2009-07-20
EA004862B1 (ru) 2004-08-26
WO2001055078A1 (en) 2001-08-02
HUP0204422A2 (en) 2003-05-28
AP2002002587A0 (en) 2002-09-30
MA26867A1 (fr) 2004-12-20
KR20020073182A (ko) 2002-09-19
PA8510601A1 (es) 2002-08-26
NZ519550A (en) 2003-11-28
JP2003520835A (ja) 2003-07-08
ATE431326T1 (de) 2009-05-15
GEP20053428B (en) 2005-01-25
EP1259474A1 (en) 2002-11-27
JP4750995B2 (ja) 2011-08-17
AR029436A1 (es) 2003-06-25
TNSN01013A1 (fr) 2005-11-10
BG106851A (en) 2003-01-31
SV2002000290A (es) 2002-07-16
ES2324281T3 (es) 2009-08-04
IL150541A0 (en) 2003-02-12
AU2214001A (en) 2001-08-07
NO20023526L (no) 2002-08-27
NO20023526D0 (no) 2002-07-24
PL357076A1 (en) 2004-07-12
CA2397960C (en) 2008-09-09
UY26550A1 (es) 2001-08-27
DZ3239A1 (fr) 2001-08-02
SK10622002A3 (sk) 2003-07-01
CZ20022474A3 (cs) 2003-06-18
DE60138686D1 (de) 2009-06-25
CN1395555A (zh) 2003-02-05
EP1259474B1 (en) 2009-05-13
HUP0204422A3 (en) 2003-08-28
CA2397960A1 (en) 2001-08-02
GT200100015A (es) 2001-10-19
EE200200404A (et) 2003-10-15
PE20011064A1 (es) 2001-10-22
ZA200205880B (en) 2003-07-23
OA12166A (en) 2003-11-07
EA200200641A1 (ru) 2002-12-26
HN2001000011A (es) 2001-06-13

Similar Documents

Publication Publication Date Title
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
ATE328605T1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
NO972615D0 (no) Benzimidazolderivater
EA199900301A2 (ru) Замещенные трициклические соединения
EA200401528A1 (ru) Производные диарилсульфидов, способ их получения и промежуточные соединения
ES2075315T3 (es) Procedimiento para la preparacion de acidos (6s)- y (6r)-tetrahidrofolicos.
CO5180578A1 (es) Inhibidores de metaloproteasas dihetero substituida que son efectivos en el tratamiento de condiciones caracterizadas por la actividad excesiva de estas enzimas
CO5190657A1 (es) Procedimiento para obtener plantas con un mayor contenido de flavonoides y constituyentes fenolicos
DE60212627D1 (de) Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
UY26550A1 (es) Éteres de dicarboxilato de calcio, métodos para su preparación y tratamiento de las enfermedades vasculares y diabetes con los mismos.
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
ATE359798T1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
ATE417856T1 (de) Motilidverbindungen
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
CO5150190A1 (es) Nuevos analogos de prostaglandina f que ocurren naturalmente y metodos de utilizar tales nuevos analogos de prostaglandina f
ATE285794T1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
ATE345123T1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE428429T1 (de) Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
SE9403831D0 (sv) A storage stable water solution for infusion I
DE50014850D1 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
ATE304846T1 (de) Verwendung von r-ibuprofen methanesulfonamied und dessen salzen zur behandlung und verhinderung von abstossungreaktionen in transplartierten organen
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE69229327D1 (de) Verwendung von Polymeren von substituierter Zimtsäure zur Behandlung von AIDS

Legal Events

Date Code Title Description
FC Application refused